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Migraine is a widespread disorder that
affects about 18% of the people, in 2/3 of
cases women (1).
The concept that migraine could be
related to some vascular diseases, such as
myocardial infarction or a stroke, have
grown over the years, mainly in migraine
with aura (2–6). In the last decades, several
studies have been carried out to under-
stand if and what the linkage could be.
Among these studies, we have found many
researches on thrombophilic disorders. In
this context, the studies focus on alterations
of coagulation factors, coagulation pro-
teins, homocysteine with MTHFR variants,
and auto-immune disorders of coagulation
such as anti-phospholipid antibodies. The
available data are sometimes difficult to
interpret. The first problem we meet is that
thrombophilic disorders usually have a low
prevalence, so we need larger sample stud-
ies to reach significant results. The second
problem could be how to correctly select
the proper study population, because some
deficits could be inherited and some others
acquired, and results could change depend-
ing on contextual factors such as preg-
nancy or anti-coagulant or estroprogestinic
therapy. The third problem, mainly deal-
ing with auto-immune coagulative disor-
ders, could be different laboratory methods
and the different positivity criteria used.
Another problem is that the prevalence of
the coagulative deficit could change with
age, so we find variable results in study-
ing children or adults. Therefore, we need
to calculate properly the sample size of
the study population. Another chance to
study the correlation between migraine
and thrombophilic disorders could be by
using the data collected through spe-
cific disease database. The main Interna-
tional Disease Database is the European
Register on anti-phospholipid syndrome
(APS). These data show that the first and
most frequent symptom of the syndrome
is a headache, probably a migraine con-
sidering the reported descriptions (7, 8).
Headaches are so important in APS to
lead expert hematologists to recommend
carrying out tests for anti-phospholipid
antibodies (aPL) in all patients present-
ing severe headaches (9). The Italian Reg-
istry of Rare Diseases is another impor-
tant source of information. It was activated
by the National Health Institute (NHI)
almost 10 years ago, through the creation
of Regional Registries. In the last Data-
base Report of Rare Diseases’ 2013 data-
base of the Piedmont Region, we find how
the number of the diagnosis of a throm-
bophilic disease performed in an headache
center is equal or higher than the one
recorded by those centers taking care of
patients who had experienced a throm-
botic event (10). Articles published more
recently correlate migraine and throm-
bophilic alterations, so we can presume
they could be co-morbid.
Coagulative factors II, V, VII, VIII, IX,
and von Willebrand have been studied in
migraineurs. The correlation between fac-
tor II mutations and migraine has been
studied throughout several smaller studies,
always with negative results (11, 12). Only
recently, a population based study reported
a higher prevalence of factor II mutation
in women suffering from migraine, but a
selection bias could be suspected because
this population had been selected among
women with a positive family history of
venous and arterial thrombosis (13). We
can find a few reports of deficit of fac-
tor VII, which seems to be non-relevant
(14, 15), and of factors von Willebrand,
VIII e IX, and various platelet alloantigens
(11, 16), topics that would be interesting
to investigate further. Most authors studied
the alterations of factor V in migraineurs,
and also in these studies the sample size
seem to be unrepresentative, and results
are controversial (11, 15, 17–20). Further-
more, some authors considered homozy-
gous mutation alone, while others consid-
ered both homozygous and heterozygous
mutation. Among the coagulative factors,
the V seems to be the most interesting
one, but larger and better designed stud-
ies are required, with more severe selection
of inclusion criteria.
Still little is known on deficit of coagu-
lation proteins C and S. The main prob-
lem of studying protein C deficit is its
low prevalence, which is around 0.4%, that
requires larger sample sizes to study and
detect any significant difference in preva-
lence between migraineurs and healthy
controls. The few available studies are too
small to clearly understand this topic (11,
18, 19). The prevalence of protein S deficit
is higher, but this type of deficit is more
complex to understand and diagnose. First
of all, laboratory methods that are used
should be clearly defined, such as the sen-
sitivity of the laboratory kit used and
what type of protein S was dosed, and is
it the total or only the free protein, all
elements needed to make a proper diag-
nosis of the type of defect (genetic or
acquired). It would be better to distinguish
inherited from acquired types of deficit,
because of the different clinical relevance
and etiopathogenesis. Inherited deficits are
easier to detect and the level of protein S can
be stable over time, on the contrary of the
acquired deficits. It is also very important
to consider and exclude iatrogenic deficits,
such as those due to anti-coagulant or
estroprogestinic therapy, or the physiologic
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lowering of protein S during pregnancy, in
order to avoid misdiagnoses. Most diffi-
cult is dealing with auto-immune protein
S deficits. In these cases, the level of protein
S could change over time, depending on
the level of auto-antibodies against protein
S itself. The prevalence of acquired deficit
of protein S is higher, this permits to study
this type of deficit with lower sample size
studies, but at least 100 people per group
are required. In the literature, we can find
very few and smaller studies, only one hav-
ing sample size and selection criteria good
enough to give reliable results (19). This
study shows how migraineurs have a higher
prevalence of protein S deficit. This data
may be even more important in view of
the correlation between estrogen, migraine,
and stroke (21, 22).
In the last 20 years, the interest in the
APS has grown more and more, and sev-
eral articles have been published looking
for any relationship between the syndrome
and migraine. Dealing with this matter, we
meet two types of problems: firstly, which
criteria is the best to consider as a positive
test; secondly, what type of laboratory test
should be used, because of the high vari-
ability in sensibility and specifically they
have. The diagnostic criteria accepted today
are still those defined in the guidelines for
the diagnosis of APS by Miyakis et al. (23,
24). Beyond the risk of thrombosis, the
link between aPL and migraine seems sup-
ported by the two studies, which have ful-
filled these criteria (25, 26). These studies
confirm that the prevalence of aPL pos-
itivity in migraineurs is higher than in
controls, both in children than in adults.
The interest in hyperhomocysteinemia
or MTHFR variants is even higher than
all the previous thrombophilic alterations.
Several authors have been studying this
topic, with smaller or larger populations,
and variable results. For several years,
hyperhomocysteinemia has been exclu-
sively linked with MTHFR mutation, but
nowadays this link does not seem to be
so direct; in fact, hyperhomocysteinemia
can be due to several other factors. Study-
ing MTHFR variants seems to have a
more speculative interest, and what could
be the practical results of this knowledge
is dubious. All these researches lead to
uncertain significance of hyperhomocys-
teinemia, the results reporting both an
increase of homocysteine in migraine with
aura compared with healthy controls or
no difference in larger population stud-
ies (27–30). Migraine with aura seems
instead to be linked with the C677T vari-
ant of MTHFR gene (31–35). Isobe is the
only researcher, who measured homocys-
teine level in cerebrospinal fluid, finding
it higher in migraineurs, mainly with aura
(36). Considering the previous reports of
the bonding between migraine and hyper-
homocysteinemia/MTHFR variants, some
authors treated migraineurs with polivi-
taminic therapy, based on a complex of
folic acid and various B vitamins, obtaining
promising results (37, 38).
In conclusion, we consider throm-
bophilic coagulative alterations quite inter-
esting for future studies, which should be
very well designed, using rigid selection cri-
teria and a correct sample size. Another
very important aspect to be considered
is to assess the impact that the therapies
used to treat these diseases would have on
migraine, especially considering that these
therapies are easy to do and at low cost.
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